Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Aytu BioScience Inc is a drug manufacturers-specialty & generic business based in the US. Aytu BioScience shares (AYTU) are listed on the NASDAQ and all prices are listed in US Dollars. Aytu BioScience employs 175 staff and has a trailing 12-month revenue of around $92.7 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $0.19 |
|---|---|
| 52-week range | $0.18 - $3.29 |
| 50-day moving average | $0.35 |
| 200-day moving average | $0.83 |
| Wall St. target price | $5.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-4.24 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.19 from 2022-09-26
| 1 week (2022-09-21) | -5.24% |
|---|---|
| 1 month (2022-08-26) | -28.84% |
| 3 months (2022-06-28) | -64.55% |
| 6 months (2022-03-24) | -83.33% |
| 1 year (2021-09-28) | -93.36% |
|---|---|
| 2 years (2020-09-28) | -84.03% |
| 3 years (2019-09-27) | 1.23 |
| 5 years (2017-09-28) | 4.06 |
| Revenue TTM | $92.7 million |
|---|---|
| Gross profit TTM | $29.2 million |
| Return on assets TTM | -12.62% |
| Return on equity TTM | -109.13% |
| Profit margin | -120.24% |
| Book value | $1.83 |
| Market capitalisation | $11.7 million |
TTM: trailing 12 months
We're not expecting Aytu BioScience to pay a dividend over the next 12 months.
Aytu BioScience's shares were split on a 1:10 basis on 8 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aytu BioScience shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Aytu BioScience shares which in turn could have impacted Aytu BioScience's share price.
Over the last 12 months, Aytu BioScience's shares have ranged in value from as little as $0.18 up to $3.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aytu BioScience's is -0.2737. This would suggest that Aytu BioScience's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Aytu BioScience has bucked the trend.
Aytu Biopharma, Inc. , a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
